EMA (EU)
GUIDANCE FINAL
Draft guideline on clinical investigation of medicinal products for the treatment of migraine and cluster headache - Revision 2
Published: 9/10/2026Detected: 9/10/2026
Summary preview
Sets out EMA expectations for the clinical investigation strategy and pivotal trial methodology for medicinal products intended for acute and prophylactic treatment of migraine and cluster headache, including key design…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026